Latest news with #NovaSeqXSeries
Yahoo
25-07-2025
- Business
- Yahoo
Why Cathie Wood Is Loading Up on This Hot Growth Stock (And Should You?)
In a market dominated by headlines about artificial intelligence (AI), cloud computing, and digital platforms, it is easy to overlook some of the most transformative developments in the life sciences. Cathie Wood, CEO of ARK Invest and known for her bold bets on disruptive innovation, has her sights set on Illumina (ILMN), a company that connects science and technology. On July 22, Wood's ARK's Genomic Revolution ETF (ARKG) bought 31,265 shares of Illumina, amounting to nearly $2.98 million, bringing the total investment in the company to $32 million. It is the ETF's 15th largest holding, comprising 2.8% of the overall portfolio. More News from Barchart UnitedHealth Stock Spirals Lower Again. Don't Buy the Dip. This Self-Driving Car Stock Is Surging on a Major Nvidia Boost Auto Revenue Keeps Plunging at Tesla. Should You Buy the TSLA Stock Dip or Run Far Away? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Let's find out if investors should follow Wood's lead and buy Illumina stock here. A High-Conviction Bet on the Future of Medicine Valued at $16.6 billion, Illumina is a biotechnology company that specializes in genome sequencing, or the process of reading and analyzing DNA. It manufactures machines (sequencers), software, and chemical kits that are used to decode the genetic material (DNA) of humans, animals, plants, and bacteria. Illumina's technology is used in hospitals and clinics, by cancer researchers, pharmaceutical companies, agricultural scientists, academics, and research institutions, among others. Some of its products include the NovaSeq X Series, iScan System, iSeq 100 System, Illumina DNA Prep, Illumina Stranded mRNA Prep, and many others. Illumina's stock price has dropped significantly since its 2021 highs, falling from above $500 to around the $100-$120 range by mid-2025. Much of this decline can be attributed to a series of self-inflicted wounds, most notably its controversial acquisition of cancer detection company Grail. However, with the Grail divestment in 2024 and a new CEO, Jacob Thaysen, in charge, Illumina appears to be refocusing on its core business of making genome sequencing cheaper, faster, and more accessible. Why the Timing Matters Now Wood is known for buying when volatility is high, particularly when she believes the market has overcorrected due to near-term concerns. Following the Grail divestment, leadership change, and a multi-quarter slump in revenue growth, investor sentiment is bearish on Illumina stock, explaining the nearly 20% drop year-to-date. However, Wood saw this as an opportunity to stock up on this rising genomic star. Illumina's financial performance appears to be stabilizing. For a growth investor like Wood, who prefers to overlook short-term earnings volatility in favor of long-term potential, these improvements are a welcome sign that the company is on the right track. In the first quarter, while revenue growth dipped slightly by 1.4%, the company improved its margins and reduced unnecessary expenses. Illumina exceeded revenue expectations and reaffirmed full-year guidance. Adjusted gross margins increased to 67.4% as a result of improved manufacturing efficiency and lower R&D costs. Adjusted earnings per share fell to $0.97 from $0.98 in the prior year's quarter. Remaining performance obligations (RPO) totaled $891 million, of which Illumina expects to generate 83% in revenue over the next year. With a reasonable debt-equity ratio of 0.63x, Illumina's balance sheet is stable. The company also generated a positive free cash flow of $208 million during the quarter. Illumina will report its second-quarter earnings on July 31. Analysts expect revenue of $1.05 billion on earnings per share of $1.01. Analysts predict a 3% drop in revenue for the full year but earnings growth of 72.9% to $4.24 per share, with an additional 9.5% increase expected in 2026. Another factor that may have influenced ARK's decision to increase its stake in Illumina is valuation. The stock is currently trading at 22 times forward earnings for 2026 and three times forward sales. Illumina has the world's largest genomics dataset, giving the company a competitive advantage. Many of Illumina's future revenue streams, including large-scale population sequencing contracts and new clinical applications in oncology and rare diseases, are not fully priced into current projections. This reasonable valuation represents a buying opportunity for a growth stock with excellent long-term prospects. What Is Wall Street Saying About Illumina Stock? Overall, the consensus on Illumina stock is a 'Moderate Buy.' Of the 22 analysts covering the stock, nine recommend a 'Strong Buy,' one suggests a 'Moderate Buy,' nine rate it a 'Hold,' one says it is a 'Moderate Sell,' and two have given it a 'Strong Sell' rating. The stock is trading close to its average target price of $106.83. However, the high price estimate of $185 suggests a rally of over 76.8% from current levels. The Key Takeaway Wood's stake in Illumina is a calculated investment based on extensive research, long-term vision, and a firm belief in the power of genomics to transform healthcare. Now, with a lower cost structure, a clear path back to profit growth, and exciting new products on the market, Illumina is poised for a turnaround. For investors with patience and a long horizon, Illumina stock represents a one-of-a-kind opportunity to invest in genomic infrastructure. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Time of India
25-06-2025
- Business
- Time of India
Dr. Lal PathLabs adds Illumina's NovaSeq X Series to expand genomics capabilities
Mumbai: Diagnostic provider Dr. Lal PathLabs Limited (DLPL) has expanded its genomics division, Genevolve , with the addition of Illumina 's NovaSeq X Series . The integration is expected to enhance the lab's capacity to deliver faster and more accurate genomic insights . The NovaSeq X system incorporates Illumina's XLEAP-SBS chemistry, offering high throughput, improved accuracy, and increased efficiency. It is stated that The NovaSeq X Plus model can process over 20,000 whole genomes per year—more than twice the capacity of Illumina's earlier models. The system is designed to support large-scale genomic research through increased speed and sensitivity. According to DLPL, the investment supports its broader efforts to improve genomic testing capabilities and contribute to the country's growing genomics landscape. Launched in 2019, DLPL's Genevolve unit focuses on DNA-based diagnostics and next-generation sequencing (NGS). The addition of Illumina's technology is expected to further strengthen its offerings in this space. Dr. Lal PathLabs and Illumina also plan to collaborate with India's scientific and medical communities to promote awareness and capacity-building for genomics-based healthcare.
Business Standard
25-06-2025
- Business
- Business Standard
Dr Lal Pathlabs strengthens its genomics capabilities with Illumina's NovaSeq X Series
Dr Lal Pathlabs (DLPL) has expanded its genomics capabilities by adding Illumina's NovaSeq X Series to its dedicated genomics division, Genevolve. With the integration of Illumina's latest technology, DLPL can now deliver faster and more accurate genomic research insights. The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina's previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what's possible in genetic sequencing. And its powerful technology allows users to unlock previously unimaginable discoveries and advancements. With the addition of Illumina's NovaSeq X Series, we are taking another step forward in driving innovation and scientific excellence, said Mr. Shankha Banerjee, CEO, Dr. Lal PathLabs Limited. This investment allows us to broaden our capabilities and contribute meaningfully to India's evolving genomics landscape. Launched in 2019, Genevolve has swiftly emerged as a DNA-based center of excellence. The addition of Illumina products further strengthens Genevolve's position as a pioneer in next-generation sequencing (NGS), enabling DLPL to deliver actionable, AI-powered insights with greater speed and sensitivity.
Yahoo
21-05-2025
- Business
- Yahoo
Gene Expression Analysis Market Outlook 2025-2030: Overcoming Challenges such as Data Complexities and Cost Barriers
Key market opportunities include rising demand for personalized medicine driven by gene expression profiling, technological advancements such as high-throughput sequencing, and the adoption of single-cell RNA sequencing. These trends are expanding applications in oncology, personalized treatments, and biomedical research. Dublin, May 21, 2025 (GLOBE NEWSWIRE) -- The "Gene Expression Analysis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to Gene Expression Analysis Market was valued at USD 5.02 Billion in 2024 and is projected to reach USD 7.84 Billion by 2030, rising at a CAGR of 7.71%. A key growth factor is the rising demand for personalized treatment approaches, where gene expression profiling helps identify individual genetic signatures, enabling more precise and effective therapies. Technological advancements, particularly in high-throughput sequencing platforms like RNA-Seq, have significantly enhanced researchers' ability to investigate the transcriptome at an unprecedented scale. The adoption of these technologies has fueled a surge in biomedical research and collaboration among pharmaceutical firms, diagnostic developers, and research institutions. In oncology, gene expression tools are increasingly used to discover biomarkers and predict treatment responses, further accelerating the expansion of the Market Driver: Advancements in Sequencing TechnologiesTechnological progress in sequencing has been a critical driver of the Global Gene Expression Analysis Market. Next-generation sequencing (NGS), in particular, has transformed gene expression studies by offering high-throughput capabilities, greater sensitivity, and cost efficiency. NGS enables the simultaneous examination of thousands of genes across numerous samples, providing deeper insights into gene activity and capabilities have broadened the use of gene expression profiling in personalized medicine, disease diagnostics, and fundamental research. The launch of high-capacity sequencers like Illumina's NovaSeq X Series, which can process over 20,000 whole genomes annually, exemplifies how enhanced throughput and reduced costs are making transcriptome analysis more accessible and widespread. This technological evolution is reshaping genomic research and reinforcing the market's long-term growth Market Challenge: Data Analysis ComplexitiesOne of the significant hurdles in the Global Gene Expression Analysis Market is the complexity involved in managing and interpreting large-scale gene expression data. High-throughput methods, such as RNA-Seq, generate vast volumes of data that require sophisticated bioinformatics tools and computational infrastructure for effective analysis. The necessity for robust data processing pipelines - from quality control and alignment to normalization and differential expression analysis - adds layers of technical difficulty. Missteps at any stage can lead to inaccurate conclusions, undermining research validity. Additionally, the requirement for high-performance computing resources and specialized data analytics expertise presents a cost and skill barrier for many institutions, especially smaller laboratories and emerging markets. Addressing these analytical challenges is vital for maximizing the utility and reliability of gene expression Market Trend: Single-Cell RNA Sequencing (scRNA-Seq)A prominent trend in the Global Gene Expression Analysis Market is the growing use of Single-Cell RNA Sequencing (scRNA-Seq). This cutting-edge technique enables researchers to profile gene expression at the individual cell level, revealing cellular heterogeneity that is otherwise masked in bulk RNA analyses. scRNA-Seq is transforming areas such as cancer biology, immunology, neuroscience, and developmental biology by allowing precise characterization of rare cell types and cellular states. This capability is driving a deeper understanding of disease mechanisms, progression, and treatment resistance. The rise of scRNA-Seq reflects a broader shift toward high-resolution, data-rich research tools that support more accurate and personalized scientific Players Profiled in this Gene Expression Analysis Market Report Merck KGaA Genscript Biotech Corporation Qiagen Bio-Rad Laboratories Takara Bio Inc. Thermo Fisher Scientific, Inc. Promega Corporation Agilent Technologies Lonza Group Ltd. New England Biolabs Inc Report ScopeIn this report, the Global Gene Expression Analysis Market has been segmented into the following categories:Gene Expression Analysis Market, by Product Type: Instruments Services Others Gene Expression Analysis Market, by Technique: RNA Expression Promotor Analysis Protein Expression & Post Translational Modification Expression Others Gene Expression Analysis Market, by Application: Drug Discovery and Development Clinical Diagnostics Biotechnology and Microbiology Others Gene Expression Analysis Market, by End User: Pharmaceutical and Biotechnology Companies Contract Research Organizations (CROs) Academic and Government Research Institutes Others Gene Expression Analysis Market, by Region: North America Europe Asia-Pacific South America Middle East & Africa Key Attributes Report Attribute Details No. of Pages 185 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $5.02 Billion Forecasted Market Value (USD) by 2030 $7.84 Billion Compound Annual Growth Rate 7.7% Regions Covered Global For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
